Group 1 - The core viewpoint of the article highlights the recent stock performance of Lepu Biopharma-B, which saw a decline of 5.01% to 8.91 CNY per share, with a trading volume of 308 million CNY [1] - Lepu Biopharma focuses on biopharmaceutical research and development in the oncology treatment field, particularly in targeted therapy and immunotherapy, and has established a comprehensive end-to-end capability in drug discovery, clinical development, CMC, and GMP-compliant production [1] - The company has built a professional sales and marketing team aimed at meeting clinical needs and providing optimized and innovative drug solutions [1] Group 2 - As of the 2024 annual report, Lepu Biopharma reported total operating revenue of 368 million CNY and a net profit of -411 million CNY [2] - A forecast for the mid-2025 performance indicates an expected profit of approximately 24 million CNY, representing a year-on-year increase of 112.18% [3]
乐普生物-B(02157)下跌5.01%，报8.91元/股